Anthem Biosciences working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026
55.95×55.95×
101.47×101.47×
33.80×33.80×
123.62×123.62×
1.36×1.44×
0.62×0.62×
1.43×1.43×
1.01×1.01×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ANTHEM₹830.15

Anthem Biosciences Ltd.

· Pharma & Health
₹ CrorePeersSYNGENEDIVISLABGLAXOAJANTPHARMIPCALABABBOTINDIAMEDANTAGLENMARKMcap ₹46,631 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)55.9555.95
Receivable Days (DSO)101.47101.47
Payable Days (DPO)33.8033.80
Cash Conversion Cycle (days)123.62123.62
Working Capital Turnover1.441.36
Asset Turnover0.620.62
Cash Conversion (CFO/Net Income)1.431.43
CFO/EBITDA1.011.01
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.